Ultrasound Refurbishment and Transducer Useful Life in 2026

Transducer Useful Life and the 2025 FDA Enforcement Record

The Philips records document a useful-life verification and distribution-control problem for specified transducers. They provide a concrete starting point for checking the affected model, serial number, service history and applicable field instructions before deciding whether a unit can return to use ^{1 2 3}.

The Three 2025 Recall Events and Product-Record Stratification

Between May and September 2025, Philips Ultrasound initiated three medical device recall events encompassing 101 individual product records in FDA's enforcement database. These actions addressed two separate underlying regulatory issues: the physical refurbishment and commercial distribution of transducers that had exceeded their operating lifespans, and the absence of clear useful-life definitions in product labeling ^{2 3 7}.

To interpret FDA enforcement data accurately, clinical engineering managers and regulatory specialists must distinguish product-level database entries from distinct recall events. OpenFDA enforcement records confirm that these 101 product listings represent three discrete recall events with different initiation dates, classifications, product codes, and underlying root causes ^{2 7}:

1. Recall Event 96994 (Initiated May 28, 2025; Class II): Philips Ultrasound initiated Class II recalls covering 21 product records (recall numbers Z-2048-2025 through Z-2068-2025) classified under product code ITX (Diagnostic Ultrasonic Transducer, 21 CFR 892.1570). FDA assigned Process Control as the root cause description. The official reason for recall stated: "Ultrasound transducer devices were refurbished beyond their useful life." The 21 affected transducer models included the following groups: curved array probes (C5-1, C5-2, 3D9-3v curved array for endovaginal obstetrics and gynecology), linear array probes (L12-3, L12-4, L8-4, L9-3, eL18-4, eL18-4 EMT, XL14-3), sector and phased array probes (S5-1, S7-2), endocavity probes (C9-5EC), volume 3D/4D arrays (V6-2 transabdominal curved volume array, VL13-5 linear volume array), and high-complexity transesophageal echocardiography (TEE) and matrix arrays (S7-3t, S8-3t, X5-1, X6-1, X7-2t, X8-2t) ^{3 7}.
2. Recall Event 97217 (Initiated July 3, 2025; Class III): Philips initiated Class III recalls covering 69 product records (recall numbers Z-2346-2025 through Z-2414-2025). The cohort comprised 67 product records classified under product code IYN (Ultrasonic Pulsed Doppler Imaging System, 21 CFR 892.1550) and 2 records under product code ITX. FDA assigned Device Design as the root cause description. The official recall reason stated: "To provide clarification and labelling to define the useful life of ultrasound transducers in the field." The openFDA database records for this event list affected transducer models directly—including the 3D6-2, 3D9-3v, C6-2, C8-4v, L12-5, and BP10-5ec—rather than specifying console platform line names ⁷.
3. Recall Event 97643 (Initiated September 5, 2025; Class III): Philips initiated Class III recalls covering 11 product records (recall numbers Z-1618-2026 through Z-1628-2026) under product code ITX. FDA assigned Device Design as the root cause description, with an identical stated recall reason: "To provide clarification and labelling to define the useful life of ultrasound transducers in the field." The 11 affected transducer models included the 3D6-2, C9-4, L12-5, L17-5, Mini Multi TEE, OMNI II TEE, OMNI III TEE, S4-1, S5-2, X3-1, and X7-2 ^{2 7}.

FDA classified event 96994 as Class II and events 97217/97643 as Class III. These are the classifications of the cited records ^{2 3 7}.

FDA Warning Letter MARCS-CMS 709948 and the 3-Year Verified Service Life

On September 9, 2025, FDA issued Warning Letter MARCS-CMS 709948 to Roy Jakobs, Chief Executive Officer of Royal Philips, concerning regulatory violations identified across Philips Ultrasound LLC facilities ¹. The warning letter followed inspections conducted by FDA investigators between January and March 2025 across three manufacturing and design facilities: Bothell, Washington (inspected January 13–31, 2025); Reedsville, Pennsylvania (inspected January 23 – March 13, 2025); and Philips Medical Systems Nederland B.V. in Eindhoven, Netherlands (inspected January 13–17, 2025) ¹.

The warning letter cited multiple quality system deficiencies under the legacy Quality System (QS) Regulation (21 CFR Part 820). The finding directly governing transducer useful life was cited as Violation 3 under 21 CFR 820.160(a) (Distribution controls): failure to establish and maintain procedures for control and distribution of finished devices ¹. Specifically, FDA observed that Philips’ design document ("Expected Service Life of Ultrasound Transducers") concluded that expected service life was verified to be 3 years for all transducers, yet refurbished transducers were distributed beyond that 3-year verified period. The inspection documented that complaints involved seven refurbished S7-3t transesophageal probes that were 5 to 10 years old and had been refurbished two to three times ¹. The warning letter recorded that the firm immediately stopped distribution of the affected refurbished transducers, initiated a recall, and updated Instructions for Use (IFU) ¹.

The May 28, 2025 recall notification announced that Philips would replace affected transducers with new units. It permitted interim clinical use according to the intended use and User Manual, including visual inspection and electrical safety testing, with removal from clinical use if inspection failed. Those are the notice's conditions; the depot hold recommended below is our editorial release-control proposal ³.

Reconciling Verified and Labeled Useful-Life Thresholds

For hospital clinical engineering teams, ISOs, and aftermarket parts distributors, the enforcement record creates a critical operational question: what is the actual, legally defensible useful life of an ultrasound transducer? Regulatory records reveal an operational tension between internal engineering verification and external field labeling ^{1 2}.

FDA recall record Z-1618-2026 (covering Recall Event 97643 for the 3D6-2 transducer) documents the Urgent Medical Device Correction Notice issued by Philips on August 19, 2025 ². That notice defined the expected service life of ultrasound transducers as follows:

• 5 years of expected service life for transesophageal echocardiography (TEE) transducers, xMATRIX transducers, and Lumify app-based transducers ².
• 7 years of expected service life for general transcutaneous transducers (curved, linear, sector) and endocavity transducers ².

Crucially, the August 19, 2025 notice directed facilities to retrieve a manufacturing certificate at transducer.philips.com to determine a probe's exact manufacturing date and calculate its remaining useful life ². For transducers exceeding the stated useful life, the August 19 notice instructed customers to conduct transducer performance tests or contact Philips for guidance ².

The warning letter’s historical verification finding and the field notice’s expected useful-life statements have different contexts. Match both to the affected model and serial number, then check the applicable recall instructions and current manufacturer information. A manufacturing certificate supplies manufacturing-date evidence; service and refurbishment history require their own records. If the basis for continued use remains unresolved, our recommendation is hold and escalation to the responsible manufacturer and clinical-engineering functions. A satisfactory test alone provides no automatic extension of supported life ^{1 2}.

Servicing Versus Remanufacturing Under FDA Guidance and the QMSR

A proposed repair can involve a lens, cable, strain relief or board. Assess the actual change and its effects against the original performance/safety specifications and intended use. The applicable guidance provides a decision process; the component name alone does not decide the outcome ^{8 9}.

FDA's May 10, 2024 Remanufacturing Guidance Architecture

On May 10, 2024, FDA issued its final guidance titled Remanufacturing of Medical Devices: Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff ⁸. As stated on its title page, the document contains non-binding recommendations expressing the agency's current enforcement interpretation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and Title 21 of the Code of Federal Regulations ⁸.

The guidance establishes that FDA distinguishes servicing from remanufacturing based on the specific physical and technical activities performed on a finished device, rather than the commercial designation of the entity performing the work. Servicing is defined as the maintenance or repair of a finished device to return it to the safety and performance specifications established by the original equipment manufacturer (OEM), for its original intended use ⁸. Remanufacturing is defined as the processing, conditioning, renovating, repackaging, restoring, or any other act done to a finished device that significantly changes the finished device's performance or safety specifications, or intended use ⁸.

Section VI.A of the guidance sets out a structured evaluation framework. Any intended-use change requires assessment; the guidance describes significant intended-use changes as likely remanufacturing. A smaller change does not automatically establish servicing ⁸. FDA also identified three specific categories of activities that the agency believes in general significantly change performance or safety specifications:

1. Changes to sterilization methods (e.g., altering the validated sterilization modality) ⁸.
2. Changes to reprocessing instructions (e.g., modifying high-level disinfection protocols) ⁸.
3. Changes to the control mechanism, operating principle, or energy type ⁸.

Crucially, Section VI.A explicitly instructs that activities resulting in these three categories of changes are likely remanufacturing, and evaluation using the guidance's decision flowchart is not recommended ⁸. For other interventions—such as component replacement, material substitution, or mechanical repair—the guidance provides a decision logic (Questions A1 through A3) to evaluate whether the activity significantly changes the performance or safety specifications of the device as a whole, taking into account cumulative changes ⁸.

This decision logic directly intersects with diagnostic ultrasound hardware through Appendix C of FDA's February 2023 guidance, Marketing Clearance of Diagnostic Ultrasound Systems and Transducers ⁹. Appendix C explicitly states: "Transducers may be remanufactured by the OEM, or entities other than the OEM ... Examples of actions that could be considered remanufacturing are changing the acoustic stack, electrical component, or patient-contact material" ⁹. Furthermore, Appendix C establishes the regulatory consequence: "non-OEM replacement transducers and remanufactured transducers are new medical devices ... required to have a cleared 510(k) prior to being marketed" ⁹. When an ISO replaces an acoustic lens (a patient-contact material) or a micro-coaxial cable bundle (an electrical component), the intervention touches components identified in Appendix C as potential remanufacturing triggers ^{8 9}.

Scope of FDA Regulatory Jurisdiction and OEM Authorization

Independent repair facilities must understand the regulatory boundaries governing third-party maintenance. Warning Letter MARCS-CMS 709948 was issued to Royal Philips concerning Philips Ultrasound LLC as the original equipment manufacturer holding cleared 510(k) applications under product codes IYN and ITX ^{1 9 10}. Its inspectional findings address the manufacturer's internal quality system and distribution controls ¹.

Under FDA’s policy for entities performing solely servicing—described in FDA's 2018 Report on the Quality, Safety, and Effectiveness of Servicing of Medical Devices and referenced in the May 2024 guidance—entities that perform strictly defined servicing are not required to register their establishments with FDA, list devices, or comply with the Quality System Regulation ^{8 11}. However, if an independent depot performs activities that significantly change specifications or intended use—such as altering the piezoelectric crystal stack or using non-equivalent lens formulations that alter acoustic transmission or thermal properties—that depot becomes a remanufacturer under 21 CFR 820.3 ^{8 9}. As a remanufacturer, the entity becomes legally obligated to register its establishment, list devices, comply with current quality system requirements, report adverse events under 21 CFR Part 803, report corrections and removals under 21 CFR Part 806, and assess the applicable marketing-submission requirements, including 510(k) where required, before commercial distribution ^{8 9}.

The May 2024 guidance excludes from its flowchart activities performed on behalf of or explicitly authorised by the OEM where they return the device to its original performance and safety specifications and intended use. The OEM evaluates and documents those activities through its QMS and retains its regulatory responsibility. The identity of a contractor or an authorisation letter alone is insufficient to establish the exception ⁸.

Section VI.B, printed page 10, recommends documenting the decision and its rationale. Its minimum list covers product name, including model and serial number if applicable; dates of activities, assessment and determination; device description; planned activities and the components, parts or materials involved; the remanufacturing determination; references supporting the decision; and signatures. Rongtao's proposed release file additionally identifies the acceptance specifications, test evidence and personnel qualifications ⁸.

Chronology of the QMSR and Methodological Attribution

A critical legal detail involves the chronology of FDA's Quality Management System Regulation (QMSR). FDA published the QMSR Final Rule amending 21 CFR Part 820 on February 2, 2024, with an effective date of February 2, 2026 ¹². The QMSR harmonizes FDA's good manufacturing practice requirements with the international standard ISO 13485:2016 (Medical devices — Quality management systems — Requirements for regulatory purposes) ¹².

The September 9, 2025 warning letter applies the legacy QS provisions to that inspection. Current activities require assessment under the now-effective QMSR. The release procedure below is Rongtao Medical’s editorial recommendation, with applicable requirements determined by the actual entity and activity ^{1 12}.

Where a Probe's Cleared Baseline Lives: What FDA 510(k) and Recall Records Show

A probe’s applicable configuration needs its own device records. Search by exact model, intended application, compatible system and relevant changes, then identify the specifications available in public clearance documents and those requiring current IFU or manufacturer service information. Product-code filing counts alone leave those model-to-system links unmeasured ⁹.

Product-Code Definitions and Modality-Agnostic Exclusions

The hardware cohort uses four specified Class II product-code groups, with definitions linked to the individual FDA classification records:

• IYN: ultrasonic pulsed Doppler imaging system, 21 CFR 892.1550 ¹⁰.
• IYO: ultrasonic pulsed echo imaging system, 21 CFR 892.1560 ¹³.
• ITX: diagnostic ultrasonic transducer, 21 CFR 892.1570 ¹⁴.
• OBJ: intravascular ultrasound catheter, 21 CFR 870.1200, with the stated intracardiac and intraluminal visualization scope ¹⁵.

QIH is a Class II automated radiological image-processing software code under 21 CFR 892.2050. Its definition covers specified nonadaptive AI algorithms; it is excluded from this hardware cohort. That is our cohort rule, not a claim that every device within a hardware code is a console or reusable external probe ¹⁶.

Retrieve a named model’s configuration rather than infer it from counts

Philips’ K132304 EPIQ summary contains a specific L12-3 indications-for-use statement. That is a direct model-to-system link in a clearance document, including the named system and mode/application matrix. Start a retrieval record with that actual model and document, rather than assume every probe’s evidence resides under one product code ¹⁷.

The later K222648 summary concerns the 5000 Compact Series. Its comparison tables list probes and system configurations including L12-3; a comparison-table entry needs to be read in its stated column and purpose. K260123, a 2026 EPIQ submission, instead introduces eV14-2v. A newer system-family document therefore requires an exact-model check before it is used for an older probe ^{18 19}.

For an actual incoming unit, identify applicable subsequent changes and the present compatible system/software configuration. A public summary provides selected information; the actual service acceptance criteria, reprocessing instructions and current manufacturer notices need their own controlled sources. Our proposed release record should cite the document supporting each criterion and show any unresolved gap. It should not equate a general premarket acoustic-output ceiling with the model’s repair acceptance specification.

Northeast Scientific’s K200195 and Abbott’s K251211 are named clearance examples for reprocessed intravascular/intracardiac ultrasound catheters. Their technology and route should be read directly; these examples provide no general conclusion about external reusable probes or the legality of a specific servicing activity ^{20 21}.

Historical recall root causes by product code

The following descriptive comparison groups product records by IYN, IYO, ITX and OBJ codes. These are mixed administrative groups: event 97217 includes IYN-coded transducer products, and ITX also includes probe covers. Keep the code labels when reading the root-cause distribution ⁷.

The archived recall snapshot contains 550 product records across IYN (298), ITX (147), IYO (82) and OBJ (23), excluding two modality-agnostic QIH records. These historical totals are separate from a later live API query. The comparison uses official root-cause labels and keeps an “all other coded causes” residual for categories outside the displayed labels ⁷.

Across the IYN/IYO groups, Device Design accounts for 127 records (112 IYN and 15 IYO), and Software design for 119 (94 IYN and 25 IYO). Among 147 ITX records, Process control accounts for 49 (33.3%), Other for 30 (20.4%), Device Design for 23 (15.6%), No Marketing Application for 18 (12.2%) and Software design for 5 (3.4%). The remaining 22 records include Process design, Under Investigation by firm and other coded categories. “Other” and “Under Investigation” are different FDA labels, so the figure preserves that distinction ⁷.

The ITX records include the 21 Philips product records for probes refurbished beyond useful life (event 96994). All 18 No Marketing Application records in event 87958 concern ultrasonic transducer covers recalled for lacking a 510(k) for use in a natural or surgical opening. Thus even a standalone-transducer product-code group contains accessories, and multiple product records can share an event. Read the actual reason before deriving a repair or release decision; the counts provide no field-failure denominator ^{2 7}.

FDA-Recognized Ultrasound Consensus Standards and the July 2, 2028 Transition Window

If a procurement specification or service contract requires conformity with an FDA-recognized standard, identify the exact edition and applicable scope. Premarket type-testing and post-repair testing answer different questions; specify the evidence required for the actual work ^{22 23 24 25}.

Active Recognitions and the July 2, 2028 Transition Window

Under Section 514(c) of the FD&C Act (21 U.S.C. 360d(c)), FDA recognizes national and international consensus standards that medical device sponsors can reference in premarket submissions (510(k), PMA, De Novo) to satisfy regulatory requirements ^{22 23 26 27}. A programmatic audit of FDA's Recognized Consensus Standards Database conducted by Rongtao Medical on November 6, 2026 (covering 1,898 normalized standards across all medical specialties) identifies 19 standards governing diagnostic, therapeutic, and surgical ultrasound equipment and acoustic field characterization in the Radiology task group ^{22 23 27}.

On May 26, 2025, FDA updated its database pursuant to Recognition List 064 (published in the Federal Register on June 26, 2025, 90 FR 27312) ²⁶. This update recognized several revised International Electrotechnical Commission (IEC) ultrasound standards while establishing transition expiration dates for prior editions ^{22 23}:

1. IEC 60601-2-37 Edition 3.0 (2024-07) (Medical electrical equipment — Part 2-37: Particular requirements for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment): Entered on May 26, 2025 under Recognition #12-380 as an active, complete recognized standard with no transition expiration date ^{22 26 28}.
2. IEC 60601-2-37 Edition 2.1 (2015): Maintained under Recognition #12-293 with an established Transition Expiration Date of July 2, 2028 ^{23 26}. Until July 2, 2028, FDA will accept declarations of conformity to either Edition 2.1 or Edition 3.0 in premarket submissions. After July 2, 2028, Edition 2.1 will be retired, and declarations of conformity to the older edition will no longer be accepted for premarket clearance ^{22 23 26}.
3. Hydrophone Calibration Standards: FDA entered IEC 62127-2 Edition 2.0 (2025-01) under Recognition #12-379 and IEC 62127-3 Edition 2.0 (2022-12) under Recognition #12-377 on May 26, 2025 ²⁶. Their predecessor editions—Edition 1.2 (Recognition #12-291, entered August 14, 2015) and Edition 1.1 (Recognition #12-279, entered July 9, 2014)—were assigned an identical Transition Expiration Date of July 2, 2028 ²⁶. IEC 62127-1 Edition 2.0 (2022-03) remains recognized under Recognition #12-343 (entered May 30, 2022) with no transition expiration stated on the individual record ²⁹.
4. Acoustic Output Index Measurement: IEC 62359 Edition 2.1 (2017-09) (Ultrasonics — Field characterization — Test methods for the determination of thermal and mechanical indices related to medical diagnostic ultrasonic fields) remains recognized under Recognition #12-316 (entered June 7, 2018), as shown by its individual record ³⁰.

Premarket consensus standards and in-service testing

The November 6, 2026 recognition search used here returned no rows for IEC 62353 or IEC 63077. That is a dated status statement about the named standards, not a statutory exclusion of maintenance or refurbishment standards as a class ²⁷.

IEC’s catalogue describes IEC 62353:2014 as recurrent testing and testing after repair of medical electrical equipment. IEC 63077:2019 addresses good refurbishment practices for medical imaging equipment. Select the relevant technical procedure for the device, activity and contract, keeping those scopes visible ^{24 25}.

A unit test report establishes the work and results it actually records. It is distinct from an FDA clearance. A claim that either named standard is FDA-recognised would conflict with the dated search above; a broader statement about all maintenance standards would need its own evidence. Match each contractual conformity statement to its actual standard edition, applicable scope and test record ^{8 27}.

South Africa's October 2026 Guidelines: Investigative Standards and Statutory Limits

In October 2026, the Competition Commission of South Africa published its Final Guidelines on Repair, Service and Maintenance Aftermarkets pursuant to Section 79(1) of the Competition Act No. 89 of 1998, as amended ^{4 31}. The document, structured across 10 sections with paragraphs 1 through 76 numbered continuously, articulates the Commission's enforcement approach toward secondary equipment markets ⁴.

Sectoral Scope and Legal Character Under Section 79

Healthcare technology managers and aftermarket distributors must understand the exact legal character of the Guidelines. The Commission issued the document under Section 79(1) of the Competition Act, which authorizes the Commission to publish guidelines expressing its policy approach ^{4 31}. Paragraph 8 and paragraph 36 define its legal boundaries:

• Paragraph 8 establishes that the Guidelines are non-binding under Section 79(4) of the Act, and expresses the Commission’s policy approach. Furthermore, under Section 59(3)(h) of the Act, the Competition Tribunal "must consider whether conduct is substantially the same as conduct regarding which Guidelines have been issued" when determining administrative penalties ^{4 31}.
• Paragraph 36 explicitly clarifies that the Guidelines do not create any substantive legal obligations that do not already arise from the Act. In its October 5, 2026 media statement, the Commission reiterated that the document articulates how it will investigate potential vertical restraints (Section 5) and abuse of dominance (Sections 8 and 9) in secondary repair and maintenance markets ^{4 32 31}.

Regarding sectoral coverage, paragraph 39 explicitly identifies sectors where OEMs "may find these guidelines relatively more applicable", listing mobile phones/tablets/consumer electronics (39.1), audiovisual equipment (39.2), white goods (39.3), "Medical equipment and devices" (39.4), and back-up water and electricity systems (39.5) ⁴. Conversely, paragraph 38 expressly excludes automotive aftermarkets, which remain governed by separate automotive industry guidelines ⁴. Paragraphs 34 through 36 establish that the Guidelines focus primarily on conduct occurring outside the initial warranty period, while reserving the Commission's authority to examine certain warranty-period restrictions that unreasonably distort downstream competition ⁴.

Secondary Market Definition and Dominance Assessment

Section 7 of the Guidelines provides a case-specific framework for relevant-market and market-power assessment. The following are our editorial applications of selected, non-exhaustive questions in paragraphs 48 and 50; they are not findings about a particular hospital or ultrasound platform ⁴:

1. Could the purchaser reasonably foresee lifetime repair and parts costs? Review tender disclosures, pricing schedules, expected-use assumptions and the information available at purchase.
2. What would switching actually cost? Compare equipment replacement, training and implementation costs with the remaining useful life and available alternatives, rather than presume that switching is prohibitive.
3. Which inputs are genuinely brand-specific? Check the actual model, interfaces, compatibility documentation and available substitutes.
4. Who controls the required repair inputs, and on what terms? Obtain access conditions for parts, diagnostic tools, service information and logs, including any documented safety justification.

Whether a single-brand aftermarket is appropriate depends on the evidence and the Commission's assessment. Market power within that secondary market is then assessed under the statutory dominance thresholds set out in Section 7 of the Competition Act (Section 7 covers at least 45%; at least 35% but below 45% unless lack of market power is shown; and below 35% where market power exists) ^{4 31}.

Aftermarket Conduct Under Commission Scrutiny

Section 8 of the Guidelines (paragraphs 52 through 69) details the specific commercial practices the Commission will scrutinize ⁴:

• Restrictions on Access to Spare Parts (Section 8.1, paragraphs 55 through 61): Paragraph 55 states that restricting independent service providers from accessing replacement parts impedes aftermarket competition. Paragraph 59.1 notes that the Commission will regard refusal to supply spare parts to ISPs as a serious category of restriction. Paragraph 59.2.2 observes that deploying software locks, digital pairing, or cryptographic handshakes to block functional replacement components warrants close scrutiny. However, paragraph 59.2.4 establishes a critical safety carve-out: conditional supply, accreditation, or activation controls confined to genuine safety or security components "will not ordinarily be treated as an indirect restriction" provided that such controls are objective, transparent, and non-discriminatory, and an accredited ISP is granted access on terms no less favorable than authorized service providers ⁴. Crucially, paragraph 61 preserves the statutory onus of proof under the Act, while expecting OEMs to substantiate objective justifications for parts supply restrictions ⁴.
• ISP Foreclosure and Consumer Penalties (Section 8.2, paragraphs 62 through 69): Paragraph 67.3 notes that the Commission may consider whether repair inputs (which excludes spare parts under footnote 7) are supplied only on condition of acquiring additional goods or services. Paragraph 67.5 examines whether accreditation or certification requirements imposed by OEMs are consistent with legitimate quality, safety, or technical considerations, and proportionate to those objectives ⁴.
• Warranty Forfeiture (paragraphs 68 and 69): Paragraph 69 examines OEM warranty terms that penalize customers for using third-party maintenance. While OEMs may exclude warranty liability for damage directly caused by improper ISP repairs, paragraph 69.6 establishes that whether an ISP's workmanship caused the specific defect "will be considered a relevant factor" in determining whether warranty cancellation constitutes an exclusionary act under Section 8 of the Act ^{4 31}.
• Objective Justifications (Section 9, paragraphs 70 through 74): Section 9 provides that OEMs may defend restrictive practices by demonstrating pro-competitive efficiency gains, protection of legitimate intellectual property rights (paragraph 73.1), or genuine patient safety and regulatory compliance requirements (paragraph 73.2) ⁴.

Throughout the Guidelines, the Commission uses investigative language—stating that it "will regard as a serious category of restriction", "may investigate", and "will consider" specific conduct under rule-of-reason legal standards—rather than enacting automatic administrative prohibitions ^{4 32 33 31}.

Pakistan's S.R.O. 1450(I)/2026: Refurbishment Registration, Import Requirements, and Age Profiling

On September 1, 2026, the Drug Regulatory Authority of Pakistan promulgated the Medical Devices (Refurbishment) Regulations, 2026 under Statutory Notification S.R.O. 1450(I)/2026, issued pursuant to Section 24 of the DRAP Act, 2012 read with Rule 76 of the Medical Devices Rules, 2017 ⁵. This statutory instrument formally regulates medical device refurbishment across Pakistan, establishing explicit licensing routes for both domestic and imported equipment ⁵.

Statutory Pathways, Applicant Categories, and Application Forms

Regulation 3(2) governs applicant eligibility, restricting applications to two commercial categories: (a) a licensed local manufacturing establishment, including an authorized third-party refurbisher; or (b) a licensed importer acting as an authorized representative of an accredited foreign legal refurbisher ⁵. Regulation 3(3) establishes four distinct application forms stratified by risk class and supply origin, while Regulation 3(4) establishes the corresponding approval certificates ⁵:

• Form 1R: Application for enlistment of locally refurbished Class A medical devices (resulting in Certificate Form 5R) ⁵.
• Form 2R: Application for enlistment of imported refurbished Class A medical devices (resulting in Certificate Form 6R) ⁵.
• Form 3R: Application for registration of locally refurbished Class B, C, or D medical devices (resulting in Certificate Form 5R) ⁵.
• Form 4R: Application for registration of imported refurbished Class B, C, or D medical devices (resulting in Certificate Form 6R) ⁵.

The proviso to Regulation 3(2) establishes categorical exclusions: single-use, implantable, and disposable medical devices are strictly excluded from refurbishment, and the Authority reserves the right to issue a negative list of ineligible products ⁵. Furthermore, substantive remanufacturing that alters original performance specifications, clinical mechanisms, structural design, or intended purpose falls outside the scope of S.R.O. 1450(I)/2026 and is governed by general manufacturing provisions ⁵.

Mandatory Quality System, Technical File, and Operational Conditions

Regulation 4(1) imposes ten cumulative conditions (clauses a through j) that refurbishers and importers must satisfy ⁵:

1. Quality Management System (4(1)(a)): The establishment must maintain a quality management system certified to relevant international standards adopted by DRAP, with medical device refurbishment explicitly within its certified scope ⁵.
2. Good Refurbishment Practices (4(1)(b)): The refurbisher must comply with Good Refurbishment Practices for Medical Devices (GRPMD) aligned with international standards adopted by the Authority ⁵.
3. Distinct Labeling (4(1)(c)): The refurbished device must bear prominent labeling marked "Refurbished" alongside a new and distinct catalog or code number, the name and premises of the legal refurbisher, establishment license number, original date of manufacture, and date of refurbishment ⁵.
4. Technical Documentation (4(1)(d)): A comprehensive model technical file must be maintained, incorporating OEM intended-use and performance baselines, a Risk Management File, software verification and validation for active software components if applicable, traceability of replaced sub-assemblies and critical parts, and Essential Principles/GSPR documentation ⁵.
5. Conformity and Testing Evidence (4(1)(e)–(f)): The declaration under 4(1)(e) confirms compliance with the Act/rules and, for imports, country-of-origin law, with no significant performance/safety/intended-use change. Under 4(1)(f), submit the test/analysis report or CoA demonstrating standards and general safety/performance conformity ⁵.
6. Authorisation documents: distinguish a manufacturer’s authorisation of a third-party refurbisher, appointment of the Pakistani operator under 4(1)(h), and the importer’s agency/authorisation evidence under Regulation 3 and Forms 2R/4R. Verify the issuer, recipient and applicable local/import route for the actual applicant ⁵.
7. Age Profiling (4(1)(i)): The refurbished equipment must comply with age profiling limits notified in guidelines issued by DRAP ⁵.
8. Refurbishment certificate (4(1)(j)): Submit the refurbisher-issued certificate confirming GRPMD refurbishment without significant alteration of intended use, safety or performance specifications, and compliance with the Act, rules, applicable ISO/IEC standards and GSPR. A per-unit release sheet in the workflow below is an editorial practice; this paragraph does not establish its frequency as a statutory requirement ⁵.
9. Radiation-emitting local equipment (4(1)(g)): The stated PNRA radiological calibration precedes final QC batch release for locally refurbished radiation-emitting devices. Assess that provision for the actual equipment; it is separate from the declaration and test-report clauses ⁵.

Regulation 4(2) requires local refurbishers to possess competent technical personnel, dedicated workshops, calibrated test instruments, and an established after-sales maintenance and spare-parts support capability ⁵.

Regulation 5 governs enforcement, providing for a show-cause notice and a 15-day written response period prior to suspension or cancellation of an enlistment or registration ⁵. Regulation 6 specifies that fees are levied in accordance with the DRAP (Fee and Levy) Rules, 2022, while Regulation 7 notes that the underlying Medical Devices Rules, 2017 apply mutatis mutandis ⁵.

Inapplicability of Provisional Registry Listings to Refurbishment Decisions

Clinical engineering managers and equipment distributors evaluating market entry into Pakistan must exercise caution regarding DRAP's provisional medical device registry workbooks. DRAP's official web portal explicitly states that these provisional lists "are only meant for review and feedback from stakeholders", may contain "errors or omissions", that DRAP "bears no responsibility for completeness and accuracy", and that they should not be relied on for litigation, claims, research, citations or statistical analysis ³⁴.

The provisional registry is unsuitable for determining a product’s refurbishment eligibility. Use the applicant, device and technical-file requirements in S.R.O. 1450(I)/2026, including the applicable authorization and age-profile conditions ^{5 34}.

European Union UDI Attribution and the Boundaries of MDR Article 16

In the European Union, Regulation (EU) 2017/745 on Medical Devices (MDR) establishes strict legal boundaries governing equipment maintenance, component replacement, relabeling, and refurbishment ³⁵. Commercial entities operating in the European secondary market must navigate the legal responsibilities defined by MDR Article 16, Article 23, and guidance from the Medical Device Coordination Group (MDCG) ^{35 6 36}.

MDCG 2026-5: UDI Assignment Remains Exclusively with the Legal Manufacturer

In July 2026, the European Commission's Medical Device Coordination Group released a position paper titled MDCG Position Paper: UDI Assignment Between Manufacturers and Distributors (MDCG 2026-5) ⁶. The paper addresses differing interpretations regarding distribution agreements structured under MDR Article 16(1)(a): specifically, where a distributor markets a medical device under its own name, registered trade name, or registered trade mark, but enters into a contractual agreement with the manufacturer under which the manufacturer remains identified as such on the label and retains full legal responsibility under the MDR ^{35 6}.

MDCG 2026-5 provides the following nonbinding explanation of obligations arising from the MDR for economic operators ⁶:

1. Exclusive Manufacturer Responsibility: UDI assignment must be made solely by the legal manufacturer. Under MDR Article 27(3), the manufacturer is legally responsible for assigning Basic UDI-DIs and UDI-DIs and uploading device identifier data to EUDAMED under Article 29 ^{35 6}.
2. Delegable Practical Execution: Quoting the EU UDI Helpdesk, MDCG 2026-5 clarifies that "the manufacturer may in principle delegate the practical operation of UDI assignment and application to a third party (e.g. under a contractual agreement), however the ultimate legal liability for complying with UDI obligations remains with the manufacturer" ⁶. Manufacturers may contractually delegate the physical application of barcode carriers and labels, provided legal liability remains undivided ⁶.
3. Prohibition of Distributor-Assigned UDIs: For the Article 16(1)(a) exception scenario, assignment and EUDAMED device registration remain the exclusive responsibility of the legal manufacturer. No distributor or third party may assign UDIs in its own name for a device where the original manufacturer remains identified on the label ^{35 6}.

When Refurbishment Triggers Full Manufacturer Status Under Article 16(1)

Under MDR Article 2(30), a manufacturer is defined as any natural or legal person who manufactures or fully refurbishes a device or has a device designed, manufactured or fully refurbished, and markets that device under its name or trademark ³⁵. Under Article 2(31), "fully refurbishing" is defined as completely rebuilding a device already placed on the market or put into service, or making a new device from used devices, to bring it into conformity with the MDR, combined with the assignment of a new lifetime to the refurbished device ³⁵.

Where an aftermarket entity modifies an ultrasound console or transducer in a manner that affects compliance, it triggers MDR Article 16(1). Under Article 16(1), a distributor, importer, or other natural or legal person assumes all statutory obligations of a legal manufacturer if it performs any of three actions ³⁵:

• Article 16(1)(a): Makes a device available on the market under its own name, registered trade name, or registered trade mark (except where a distributor or importer enters into an agreement with a manufacturer whereby the manufacturer is identified as such on the label and remains responsible for meeting manufacturer obligations) ³⁵.
• Article 16(1)(b): Changes the intended purpose of a device already placed on the market or put into service ³⁵.
• Article 16(1)(c): Modifies a device already placed on the market or put into service in such a way that compliance with the applicable requirements may be affected ³⁵.

Guidance document MDCG 2018-6 (Clarifications of UDI Related Responsibilities in Relation to Article 16 of Regulation (EU) 2017/745) details the regulatory obligations when Article 16(1) is triggered ³⁶. The entity must register as a manufacturer in EUDAMED, obtain a Single Registration Number (SRN), compile technical documentation under Annexes II and III, establish the quality management system required by Article 10(9), undergo full conformity assessment with a Notified Body where required by the device's classification, assign its own Basic UDI-DI and UDI-DI, apply its own UDI carrier to the physical product, and maintain technical documentation for at least 10 years after the last device covered by the EU declaration of conformity has been placed on the market (Article 10(8)) ^{35 36}.

Component Maintenance Under Article 23 Versus Relabeling Under Article 16(2)

MDR Article 23(1) governs spare parts supply, providing that any natural or legal person who makes available an item specifically intended to replace an identical or similar integral part or component of a device that is defective or worn—to maintain or restore the function of the device without changing its performance, safety characteristics, or intended purpose—must ensure that the item does not adversely affect the safety and performance of the device, keeping supporting evidence available to competent authorities ³⁵. Conversely, under Article 23(2), where a replacement item significantly changes the performance, safety characteristics, or intended purpose of the device, that replacement item is considered to be a device in its own right and must meet all requirements laid down in the MDR ³⁵.

Article 16(2)(a) covers provision, including translation, of manufacturer-supplied information under Annex I section 23 relating to a device already placed on the market, and further information necessary to market that device in the relevant Member State. Article 16(2)(b) concerns changes to outer packaging of a device already placed on the market where necessary for that Member State and performed without affecting original condition. Opening or damaging packaging needed to maintain sterility creates the stated presumption that original condition is adversely affected ³⁵.

Article 16(3) requires the distributor or importer to identify the activity and its name, registered trade name or registered trade mark, registered place of business and contact address on the device. Packaging or an accompanying document is the alternative where marking the device is impracticable. The required QMS must also be in place. Article 16(4) requires at least 28 days’ prior notice to the manufacturer and competent authority, a sample/mock-up on request, and submission of the notified-body QMS certificate to the competent authority within that period. Those conditions should accompany any proposed translation/repackaging exception ^{35 36}.

A Device-Specific Release Record

The following decision matrix presents a structured editorial procedure recommended by Rongtao Medical to assist clinical engineering managers, ISO leads, and equipment distributors in organizing compliance evidence. It represents a practical organizational tool, distinct from statutory mandates.

Consider a hypothetical six-year-old Philips curved-array probe assumed to belong to a model cohort in the cited correction record. Its prior service history is unavailable. First verify the exact model/serial applicability and required recall actions; use the manufacturing certificate as date evidence, then request refurbishment and service records. The five-/seven-year notice and the historical three-year verification finding need their actual context. The missing history leaves this scenario on hold for manufacturer/clinical-engineering escalation ^{1 2}.

A proposed lens replacement also needs a documented activity assessment: original specifications, material equivalence, patient-contact and reprocessing effects, and cumulative changes. OEM origin is not the general decisive test. For a Pakistan destination, verify the actual applicant, manufacturer/refurbisher relationship and import documents under Regulation 3 and the relevant forms. Test results become one part of the evidence. Release is considered only after documented closure of applicable lifetime, recall, activity, testing and destination requirements; unresolved gaps remain a hold. This is an editorial example, not a report of a customer release ^{8 9 5}.

For cross-border supply chains, distributors must separately classify whether a shipment represents an unworked component, a serviced unit, or a fully refurbished device. The product’s actual condition and applicable jurisdiction determine its regulatory assessment. Refurbishment registration in Pakistan under S.R.O. 1450(I)/2026 requires independent destination compliance regardless of prior clearance in the United States or the European Union ^{5 35}.

Rongtao Medical's Published Service Scope

Rongtao Medical's published profile describes an independent ultrasound service organization founded in 2013, serving healthcare facilities, ISOs, and distributors across more than 140 countries and regions from a 3,000 m² technical and warehousing center in Guangzhou, China ^{37 38}. The company maintains an inventory of more than 3,000 parts SKUs and employs an engineering team of more than 35 senior technical specialists ³⁷.

Rongtao Medical operates under quality management systems certified to ISO 13485:2016 (with an official scope covering ultrasound board repair and tested replacement-parts sales) and ISO 9001:2015 ^{37 38}. In its published quality procedures, the firm specifies a mandatory 48-hour real-machine testing protocol for repaired electronic boards prior to release, supplying photographic and video test records upon customer request ^{37 38}. These statements describe published company operating procedures, rather than independent regulatory findings of product-level conformity to named IEC standards ^{37 38}.

The published service profile indicates a standard repair turnaround time of 5 to 8 business days and a typical 90-day warranty, with extended warranty options available upon request ³⁷. Rongtao Medical maintains service compatibility across major commercial ultrasound console platforms ³⁷. Rongtao Medical is an independent service organization; OEM affiliation, endorsement, or manufacturer refurbishment authorization must be established through case-specific documentation. Where an equipment tender or national authority (such as Pakistan under S.R.O. 1450(I)/2026) requires direct OEM authorization, buyers must obtain the necessary manufacturer appointment documents ⁵. Clinical engineering managers and parts distributors can contact Rongtao Medical to discuss specific console models, transducer faults, and available test documentation.

Conclusion

Clinical engineering directors and aftermarket distributors should use the 2025 Philips enforcement record as a practical prompt to reconcile internal design verification documents with commercial field labeling. While Warning Letter MARCS-CMS 709948 highlighted an internal engineering document verifying expected service life to 3 years, the August 19, 2025 correction notice, issued before that warning letter, specified expected useful lives of 5 and 7 years for the named transducer families ^{1 2}. These documents must be reconciled for the specific model under review; neither document establishes a universal lifetime across the ultrasound industry.

Regulatory assessments must respect jurisdictional boundaries. In the United States, FDA distinguishes servicing from remanufacturing based on the physical activity and its impact on specifications, with Appendix C of the ultrasound guidance highlighting acoustic stack, electrical, and patient-contact components as potential remanufacturing triggers ^{8 9}. In South Africa, the Competition Commission's October 2026 Guidelines apply rule-of-reason antitrust scrutiny to OEM spare-parts restrictions and warranty voiding, while acknowledging legitimate safety and regulatory compliance defenses ⁴. In Pakistan, S.R.O. 1450(I)/2026 establishes legal enlistment and registration routes for local and imported refurbished equipment, conditioned on OEM authorization and age profiling ⁵. In the European Union, MDCG 2026-5 confirms that legal responsibility for UDI assignment remains exclusively with the legal manufacturer, even when physical application is delegated ⁶.

When procuring ultrasound maintenance or replacement parts, healthcare asset managers should provide complete device identifiers (model, serial number, date of manufacture, service history) and request calibrated test reports traceable to the serviced unit. Rongtao Medical's technical team can review published repair capabilities and 48-hour real-machine testing protocols for specific platforms, supporting transparent asset management across global healthcare markets ^{37 38}.

Method and coverage

The configuration examples use the named FDA summaries and decisions linked in the Sources. They demonstrate document retrieval, not the proportion of all probe baselines held in any filing type. Current unit acceptance needs the actual model, configuration and controlled manufacturer documentation.

The recall comparison uses the archived 58,785-record input: 550 records across the four ultrasound codes, excluding QIH. For each code and displayed cause, count the exact root-cause field; all remaining causes enter the named residual. For example the ITX residual is 147 − (49 Process control + 30 Other + 23 Device Design + 18 No Marketing Application + 5 Software design) = 22 records. This is a product-record analysis; FDA res_event_number identifies the event grouping; events 96994/97217/97643 were checked separately against FDA records on November 6, 2026 ⁷.

Consensus standards analysis reflects FDA's Recognized Consensus Standards Database as accessed on November 6, 2026, comprising 1,898 normalized active and transition recognitions across all medical specialties under Section 514(c) of the FD&C Act, with 19 standards assigned to diagnostic, therapeutic, and characterization ultrasound in Radiology ^{22 23 26 27}. Entry dates and transition expiration dates were verified against Recognition List 064 (90 FR 27312, June 26, 2025) and individual FDA recognition detail records ^{22 23 26 27}.

Legal analyses are grounded in official primary texts: Warning Letter MARCS-CMS 709948 ¹; FDA recall records Z-2048-2025 and Z-1618-2026 ^{2 3}; FDA's May 10, 2024 Remanufacturing Guidance ⁸; FDA's February 2023 Ultrasound Guidance ⁹; South Africa's Competition Act No. 89 of 1998 (as amended) and the Competition Commission's October 2026 Final Guidelines, Media Statement, and Background Note ^{4 31 32 33}; Pakistan’s final S.R.O. 1450(I)/2026 and its forms ⁵; and Regulation (EU) 2017/745 alongside MDCG 2026-5 and MDCG 2018-6 ^{6 35 36}. Non-binding guidance documents are explicitly characterized as advisory policy statements rather than statutory mandates.